Programmable cells
Commercial scalingCells are engineered as production systems, sensors, and therapeutics.
Design-build-test loops are increasingly automated.
Industry detail
Synthetic Biology
The field now depends on automation, synthesis throughput, biosecurity, and scale-up discipline.
Scaling
Industry system
Connected view
Dependencies, demand, capabilities, companies, milestones, and evidence in one workspace.
Select a node to update the detail panel.
Stage
Scaling
Companies
7
Milestones
3
Enabling stack
Global axes
Demand and adjacent markets
No records in this sample.
Core capabilities
Full records
Detailed records behind the map
Capabilities, milestones, participants, evidence, and live source checks remain available after the connected view.
Capability map
What has to work
The main technical capabilities that define progress in this industry.
DNA synthesis
Commercial scalingLower-cost synthesis expands what can be designed and screened.
Throughput and screening controls are now industry infrastructure.
Biomanufacturing scale-up
Pilot deploymentsFermentation and downstream processing determine unit economics.
More programs are reaching contract manufacturing and end markets.
Biosecurity screening
Pilot deploymentsScreening tools reduce misuse risk as design access broadens.
Standards bodies and vendors are aligning on screening workflows.
Free API layer
Live source checks
Public APIs expand the research graph while preserving neutral analytical framing.
Checking free public APIs...
Recent milestones
How far it has progressed
Observable events tied to capabilities, companies, and sources.
Benchling launches AI-enabled R&D products at SynBioBeta 2026
Synthetic biology scale increasingly depends on data systems, ordering workflows, and AI-enabled analysis rather than wet-lab tools alone.
Evidence
Biosecurity screening guidance expands for synthetic nucleic acids
Screening practices become more important as synthesis access broadens.
National biomanufacturing initiative elevates scale-up infrastructure
Policy support puts manufacturing capacity and standards at the center.
Evidence
| Date | Milestone | Capability | Related | Evidence |
|---|---|---|---|---|
| May 12, 2026 | Benchling launches AI-enabled R&D products at SynBioBeta 2026Synthetic biology scale increasingly depends on data systems, ordering workflows, and AI-enabled analysis rather than wet-lab tools alone. Synthetic Biology | Programmable cells | ||
| Apr 29, 2024 | Biosecurity screening guidance expands for synthetic nucleic acidsScreening practices become more important as synthesis access broadens. Synthetic Biology | Biosecurity screening | ||
| Sep 12, 2022 | National biomanufacturing initiative elevates scale-up infrastructurePolicy support puts manufacturing capacity and standards at the center. Synthetic Biology | Biomanufacturing scale-up |
Related participants
Company and institution map
Public companies, smaller public companies, private/startup participants, and research institutions.
Core builders / suppliers
Companies directly tied to the sector's capabilities, products, or supply stack.
Ginkgo Bioworks
DNACell programming platform
Small-cap publicUnited Statesdirect2 capabilities1 milestones1 relation
Twist Bioscience
TWSTDNA synthesis provider
Small-cap publicUnited Statesdirect2 capabilities1 milestones1 relation
Benchling
Biotech R&D data platform
PrivateUnited Statesdirect2 capabilities1 milestones
LanzaTech
LNZAGas fermentation platform
Small-cap publicUnited Statesdirect2 capabilities1 milestones
Moderna
MRNAProgrammable medicine platform
PublicUnited Statesdirect2 capabilities1 milestones
Inscripta
Genome engineering tooling
PrivateUnited Statesdirect2 capabilities1 relation
Research and public programs
Institutions and programs that support the technology path.
Related public companies
1Related public companiesRoleGeographyMarket
Related small-cap companies
3Small-cap public
Ginkgo Bioworks
Cell programming platform
Cell programming platformUnited StatesNYSE
Small-cap public
Twist Bioscience
DNA synthesis provider
DNA synthesis providerUnited StatesNASDAQ
Small-cap public
LanzaTech
Gas fermentation platform
Gas fermentation platformUnited StatesNASDAQ
Related small-cap companiesRoleGeographyMarket
Related private and startup companies
2Private
Benchling
Biotech R&D data platform
Biotech R&D data platformUnited States
Private
Inscripta
Genome engineering tooling
Genome engineering toolingUnited States
Related private and startup companiesRoleGeographyMarket
Research institutions
1Research institutionsRoleGeographyMarket
Evidence
Source list
Signals and milestones remain traceable as provider data expands the research graph.
News - May 12, 2026Benchling SynBioBeta 2026 product launchesSynBioBetaGovernment program - Sep 12, 2022Executive order on biotechnology and biomanufacturingThe White HouseGovernment program - Apr 29, 2024Synthetic nucleic acid screening frameworkU.S. Department of Health and Human ServicesCompany release - Jan 1, 2024Synthetic DNA manufacturing platformTwist BioscienceResearch paper - Jan 1, 2024Genome engineering and screening researchBroad Institute